Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, TBT Pharma is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ian Tolfree played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TBT Pharma

TBT is a dermatology start up with novel mechanisms of action. We are re-purposing generic and off patent compounds approved for oral and intravenous use for topical use to exploit our MOAs. Re-purposing allows us to get to market quickly at a fraction of the cost of developing a new molecule, shortening the time for our solutions to come to market. We will become a world leader in topical dermatology. TBT has 4 pipeline patented products that can be used to treat multiple skin conditions, with potentially millions of end users and billions in addressable market share in the United States alone.

To learn more about TBT Pharma, visit http://www.tbtpharma.com/

Contact:
Ian Tolfree, Chief Executive Officer
914-672-5006
https://www.linkedin.com/in/ian-tolfree/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved